|
The attachment hereto was issued 18 May 2005 by Dr. Mary Bell, Chair of the Breeds & Industry Equine Health Committee
Report on The Veterinary Drugs Directorate 6th Stakeholder Committee Meeting
In May of 2004, Equine Canada was invited to have a seat on the VDD Stakeholder Committee. The VDD is the branch of Health Canada that reviews and licenses veterinary drugs.
Over the last 18 years, the number of veterinary products licensed for use in horses in Canada has decreased significantly in comparison to other countries. Other species of livestock have also experienced this decrease. Drug companies have been less willing to submit new products for licensure in Canada due to the lengthy delays in review times and high fees for review.
The VDD, drawing input from the Stakeholder Committee, has increased staff and made a significant effort to decrease the backlog of products for review. They are making major improvements in this area.
Two issues, specific to the horse, were addressed at this meeting. The first was the lack of licensed products for horses. This results in the need to use products off label* and to use products that are compounded by pharmacies. The second was the paucity of equine drugs that include withdrawal times for horses intended for slaughter.**
The VDD is trying to develop a means of providing more products for those species that have few licensed specifically for them. We have been able to assure that horses are included in this category.
Because Equine Canada restructured to include the national horse industry, we now have national representation on this Committee. This allows us to improve the health and welfare of the horse in Canada.
*Off label use includes use of products licensed for humans or for other species on horses and use of products licensed for horses in a manner that is different from the recommended dose or recommended route of administration.
**The VDD has not required drug companies to provide information related to the time required to prevent a horse from going to slaughter for human consumption following the horse receiving a specific drug. The information exists on many of these licensed products but is not included on Canadian labels. Those who are currently confused on withdrawal times can refer to the following website that has been established through the private sector: www.CgFARAD.usask.ca
Executive Director Equine Canada Phone: 613-248-3433 ext. 116 Fax: 613-248-3484 e-mail: dadams@equinecanada.ca website: equinecanada.ca
|